More bad news for bank stocks
Stories about suspicious transactions may be overblown, but HSBC has plenty of other problems to worry about. Matthew Partridge reports
Claims that some of the world’s largest banks “moved large sums of allegedly illicit funds over nearly two decades”, despite “red flags” about the origins of the money, caused shares in the sector to fall on Monday, say David Pegg and Julia Kollewe in The Guardian. Barclays, HSBC and Standard Chartered were among those hit by the leak of thousands of documents showing $2trn (£1.55trn) of “potentially corrupt transactions” between 1997 and 2017 that passed through the US financial system.
For HSBC investors in particular, these headlines may feel unpleasantly familiar. Eight years ago, the bank was fined nearly $2bn, and forced to agree a deferred prosecution agreement by the US Department of Justice, for “providing banking services to drug cartels and other criminals”, says Katherine Griffiths in The Times. Its Swiss subsidiary was also hit by claims in 2007 that it had been helping clients to dodge taxes. The latest allegations could lead to a “flurry of legal claims” against it from the victims of the fraudsters whom it supposedly helped move money.
An overreaction
Calm down, says Liam Proud on Breakingviews. While it’s true that banks “could improve their systems for spotting money laundering”, the behaviour is “less scandalous than some of the headlines make it sound”. This is because the allegations are based on “suspicious activity reports” (SARs) that the banks must file with the authorities every time they think that criminal activity could be going on. Anti-money laundering systems “catch many legitimate transactions”: one estimate is that 90% of SARs turn out to be false positives. So it’s standard practice for banks to report – rather than block – them.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This report looks like the least of HSBC investors’ worries, agree Margot Patrick and Frances Yoon in The Wall Street Journal. A bigger concern is that HSBC could be put on an “unreliable entities” list in China that “would threaten the bank’s growth plans in retail banking and in the country’s securities markets”. China’s Ministry of Commerce has said such entities could “face limits on investment and staff in China”. While no companies have been put on this list yet, China’s state-owned media have named HSBC as a possible candidate.
Any action by China against HSBC would be particularly damaging given that HSBC “has invested heavily in the mainland”, says Lex in the Financial Times. China also contributes $1.5bn worth of pre-tax profits, at a time when HSBC’s earnings in the rest of the world have fallen. Having alienated Europe and America, by publicly supporting Beijing’s new security legislation in Hong Kong, the loss of Chinese support would leave it “friendless”. It’s therefore no surprise that its shares “are trading at levels last seen in the 1990s”, a demonstration of why businesses that have become “political shuttlecocks” are “not worthwhile investments”.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Chinese stocks slump on first trading day of 2025
Chinese stocks suffered in the new year from their worst first day of trading since 2016, despite a state stimulus package
By Alex Rankine Published
-
Is now a good time to buy UK housebuilders?
Recent share price falls could make UK housebuilder stocks undervalued, though there is a great deal of market uncertainty to contend with
By Dan McEvoy Published
-
Why Wise could be worth a lot more than its share price implies
Foreign-exchange transfer service Wise has the potential to become the Amazon of its sector – here's why you should consider buying this stock now
By Jamie Ward Published
-
Can The Gym Group pump up your portfolio?
Gym Group was one of the best UK small-cap stocks in 2024 and will beef up your profits this New Year
By Rupert Hargreaves Published
-
MoneyWeek's five predictions for investors in 2025
MoneyWeek's City columnist gazes into his crystal ball and sees five unexpected events in store for investors in 2025
By Matthew Lynn Published
-
How buy-and-build stocks deliver strong returns
Bunzl, DCC and Diploma became successful through buy-and-build – rolling up dozens of unglamorous businesses. How does it work and what makes it successful?
By Jamie Ward Published
-
Singapore Technologies Engineering shows strong growth
Singapore Technologies Engineering offers diversification, improving profitability and income
By Dr Mike Tubbs Published
-
Royal Mail takeover by Czech billionaire approved for £3.6bn
Royal Mail is now owned by Czech billionaire Daniel Kretinsky, following a £3.6 billion takeover
By Dr Matthew Partridge Published
-
AstraZeneca goes cheap – should you buy?
The decline in AstraZeneca’s share price is overdone given the outlook, and the stock is cheap
By Rupert Hargreaves Published
-
Why undersea cables are under threat – and how to protect them
Undersea cables power the internet and are vital to modern economies. They are now vulnerable
By Simon Wilson Published